Failure to confirm a sodium–glucose cotransporter 2 inhibitor‐induced hematopoietic effect in non‐diabetic rats with renal anemia-Reference-Cited by-同舟云学术

Failure to confirm a sodium–glucose cotransporter 2 inhibitor‐induced hematopoietic effect in non‐diabetic rats with renal anemia

Published:2020-02-05 Issue:4 Volume:11 Page:834-843
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Yamazaki Daisuke¹²,Konishi Yoshio²,Morikawa Takashi²,Kobara Hideki³,Masaki Tsutomu³,Hitomi Hirofumhi⁴,Osafune Kenji⁵^ORCID,Nakano Daisuke¹,Kittikulsuth Wararat¹,Nishiyama Akira¹^ORCID

Affiliation:

1. Department of Pharmacology Faculty of Medicine Kagawa University Kagawa Japan

2. Division of Nephrology and Hypertension Osaka City General Hospital Osaka Japan

3. Department of Gastroenterology and Neurology Faculty of Medicine Kagawa University Kagawa Japan

4. Department of iPS Stem Cell Regenerative Medicine Kansai Medical University Osaka Japan

5. Department of Cell Growth and Differentiation Center for iPS Cell Research and Application Kyoto University Kyoto Japan

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13205

Reference36 articles.

1. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

2. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension

3. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

4. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial

5. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Possible renoprotective mechanisms of SGLT2 inhibitors;Frontiers in Medicine;2023-03-09

2. Relationship Between SGLT2 Inhibitors and Hemoglobin Levels: A Retrospective Observational Study;In Vivo;2023

3. Empagliflozin Reduces Renal Hyperfiltration in Response to Uninephrectomy, but Is Not Nephroprotective in UNx/DOCA/Salt Mouse Models;Frontiers in Pharmacology;2021-12-21

4. Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease;Expert Review of Clinical Pharmacology;2021-12-02